Hospital Pharmacy and Therapeutics Committees Are Actively Considering Forest/AstraZeneca`s Teflaro and Optimer/Cubist`s Dificid for Formulary Inclusion, While Working to Streamline the Number of On-Formulary Carbapenems, Ec